US FDA Vaccine Advisors Leave Door Open For COVID Emergency Use Authorizations For Young Children
Executive Summary
Many members of FDA’s Vaccines Related and Biologic Products Advisory Committee were emphatic about not closing off the EUA pathway for COVID-19 vaccines for younger children – a bit of a contrast to FDA’s unsureness in its briefing documents for the panel. However, the committee also had a solid minority of vocal opponents to speeding up pediatric approval of COVID vaccines given new myocarditis concerns and lower risk of poor COVID outcomes.